Pharming Group (PHAR) news
Recent news
Pharming shares rise 3.8% as FDA accepts Joenja resubmission
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) for Joenja® (leniolisib) to treat children aged 4 to 11 years with activated phosphoinositide 3-kinase delta…
AInvest Wire · Jun 4, 2026Pharming Group shares up 2.7% after FDA acceptance of SNDA resubmission for Joenja for children aged 4 to 11 years with APDS
Pharming Group N.V. (Euronext: PHARM; Nasdaq: PHAR) announced on June 4, 2026, that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) for Joenja® (leniolisib) to treat children aged 4 to 11 years with activated phosphoinositide…
AInvest Wire · Jun 4, 2026Pharming Group expands research on Leniolisib for additional primary immunodeficiencies, targets phase 2 trial initiation in 2Q24
AInvest Wire · Dec 13, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.